In a recent discussion on diagnostic company funding, Acuamark CEO Bernard Peperstraete highlighted advances in blood-based diagnostics technologies.
While the industry has a lot to be proud of, especially with respect to late-stage disease detection, Acuamark has engineered the first-ever qPCR-based approach optimized for highly accurate early cancer signal detection at ultra-low abundance.
